康恩貝(600572.SH):丹蔘川芎嗪注射液抽檢不合格 拜特公司未收到核查函
格隆匯7月14日丨康恩貝(600572.SH)公佈,山東省藥品監督管理局於2020年7月9日發佈《山東省藥品監督管理局藥品質量抽檢通告(2020年第4期)》,其中公司全資子公司貴州拜特製藥有限公司(以下簡稱“拜特公司”)生產的丹蔘川芎嗪注射液(批號:20180726)可見異物檢測不合格。
經拜特公司對該批留樣樣品進行全項複核性檢驗,檢驗結果均符合規定。截止目前,市場上已無上述批號的丹蔘川芎嗪注射液在銷售、使用(該批產品目前已過法定有效期)。拜特公司未曾因上述事項進行相關產品召回的情形,也尚未因上述事項發生停產、遭受損失及賠償等情況。
截止目前,拜特公司未收到棗莊市市中區市場監督管理局抽檢相關不合格藥品核查函,且未受到監管部門的處罰、責令整改、停產等監管措施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.